The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
The Future of HIV Testing: Integration, Innovation and Inclusion Because of their speed, sensitivity and cost- effectiveness, enzyme immunoassays remain the standard screening tool for HIV infection by volume. 13 However, molecular and emerging CRISPR-based platforms represent the fastest-
However, a new wave of innovation is accelerating progress. Advances in nano- technology, biosensors, microfluidics and next-generation sequencing (NGS) are enabling earlier detection, multiplex testing, lower cost and seamless digital connectivity for real-time follow-up. Examples include: Biosensors and Lab-on-a-Chip Platforms Emerging biosensor and microfluidic systems combine biological recognition with optical or electrical detection to deliver rapid, sensitive testing from minimal samples. 15 Compact, low-cost and automated, these platforms support both early diagnosis and longitudinal monitoring in decen- tralized settings.
growing segments—driven by advances in decentralized, digitally-integrated testing. Despite these innovations, challenges in sensitivity, latency and accessibility persist, particularly in low-resource settings. Sensitivity Gaps Even the most advanced assays cannot detect HIV during the initial “eclipse” phase (up to 20 days post-infection). 14 Molecular methods such as NAAT and qPCR improve early detection but can still miss cases with very low viral loads, particularly in individuals on suppressive antiretroviral therapy. Latency Limitations No current technology can identify latent HIV reservoirs, which remain a major obstacle to eradication and cure research. Clinical Translation Barriers Bridging innovation from research to real-world use remains challenging. Economic constraints, infrastructure gaps and limited technical capacity restrict the adoption of next-generation HIV diagnostics. High-complexity assays can be costly and infrastructure-intensive, requiring stable power, cold-chain storage and skilled personnel, limiting their scalability in decentralized and low-resource settings.
Omics and Precision Diagnostics Genomic and metabolomic profiling are
paving the way for more personalized HIV care by identifying molecular signatures linked to disease progression and drug resistance. As automation improves and costs decline, precision diagnostics are becoming increasingly scalable and clinically relevant. Next-Generation POC and CRISPR Technologies Miniaturized, app-enabled point-of-care systems now integrate biosensors, microfluidics and real-time readers to deliver rapid viral load and resistance monitoring. CRISPR-Cas–based assays further enable low-cost detection of mutations and co-infections, with multiplex formats nearing clinical readiness. 16
GENengnews.com | 33
Powered by FlippingBook